2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T4cf,TP53-mutated (TP53-MT) myeloid neoplasms (MN) represent one of the most challenging disease subsets due to their distinct pathobiology, frequent association with therapy-related disease, chemo-resistant phenotype, and dismal outcomes. The prognostic impact of TP53-MT is not uniform and is influenced by disease state, allelic burden, and co-occurring cytogenetic and molecular aberrations that shape disease trajectory. While current prognostic models incorporate TP53 status, they incompletely capture the heterogeneity within TP53-MT MN. Therapeutic options remain limited, with allogeneic stem cell transplantation being the only intervention offering long-term survival in selected patients. Novel approaches, including p53 reactivators and anti-CD47 antibodies in combination with standard-of-care therapies, have been explored; however, none has yet transformed the natural history of TP53-MT MN. This review highlights the current understanding of TP53-MT MN, evolving strategies of prognostic stratification and propose a practical framework for clinical management. We further discuss the critical unmet need for collaborative, biologically informed clinical trials to improve outcomes of this challenging disease entity.31:T94f, Purpose of review TP53- mutated ( TP53 -MT) myeloid neoplasms (MN) represent one of the most challenging disease subsets due to their distinct pathobiology, frequent association with therapy-related disease, chemo-resistant phenotype, and dismal outcomes. The prognostic impact of TP53 -MT is not uniform and is influenced by disease state, allelic burden, and co-occurring cytogenetic and molecular aberrations that shape disease trajectory. While current prognostic models incorporate TP53 status, they incompletely capture the heterogeneity within TP53 -MT MN. Therapeutic options remain limited, with allogeneic stem cell transplantation being the only intervention offering long-term survival in selected patients. Recent findings Novel approaches, including p53 reactivators and anti-CD47 antibodies in combination with standard-of-care therapies, have been explored; however, none has yet transformed the natural history of TP53 -MT MN. Summary This review highlights the current understanding of TP53 -MT MN, evolving strategies of prognostic stratification and propose a practical framework for clinical management. We further discuss the critical unmet need for collaborative, biologically informed clinical trials to improve outcomes of this challenging disease entity. 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Allogeneic Stem Cell Transplantation: modality Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Allogeneic Stem Cell Transplantation (modality). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/modality/Allogeneic%20Stem%20Cell%20Transplantation\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Modalities\",\"item\":\"https://www.reachrx.ai/hub/tag/modality\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Allogeneic Stem Cell Transplantation\",\"item\":\"https://www.reachrx.ai/hub/tag/modality/Allogeneic%20Stem%20Cell%20Transplantation\"}]}}"}}]],["$","$L2f",null,{"title":"Allogeneic Stem Cell Transplantation: Research & Clinical Takeaways","description":"Review evidence by treatment modality: Allogeneic Stem Cell Transplantation — concise summaries and practical next steps.","papers":[{"doi":"10.1002/ajh.70405","pmid":"42400116","title":"Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk‐Stratification and Management","journal_title":"American Journal of Hematology","journal_issn":"0361-8609","published_at":"2026-07-03T00:00:00.000Z","url":"https://doi.org/10.1002/ajh.70405","source_score":27,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-10T13:25:25.883Z","updated_at":"2026-07-10T13:25:25.883Z","tags":[{"paper_doi":"10.1002/ajh.70405","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1002/ajh.70405","tag_type":"brand","value":"Inqovi","value_numeric":null},{"paper_doi":"10.1002/ajh.70405","tag_type":"brand","value":"Reblozyl","value_numeric":null},{"paper_doi":"10.1002/ajh.70405","tag_type":"brand","value":"Rytelo","value_numeric":null},{"paper_doi":"10.1002/ajh.70405","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1002/ajh.70405","tag_type":"condition","value":"Acute Myelogenous Leukemia","value_numeric":null},{"paper_doi":"10.1002/ajh.70405","tag_type":"condition","value":"Myelodysplastic Syndromes","value_numeric":null},{"paper_doi":"10.1002/ajh.70405","tag_type":"generic","value":"azacitidine","value_numeric":null},{"paper_doi":"10.1002/ajh.70405","tag_type":"generic","value":"decitabine/cedazuridine","value_numeric":null},{"paper_doi":"10.1002/ajh.70405","tag_type":"generic","value":"imetelstat","value_numeric":null},{"paper_doi":"10.1002/ajh.70405","tag_type":"generic","value":"lenalidomide","value_numeric":null},{"paper_doi":"10.1002/ajh.70405","tag_type":"generic","value":"luspatercept","value_numeric":null},{"paper_doi":"10.1002/ajh.70405","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1002/ajh.70405","tag_type":"level_of_evidence","value":"7","value_numeric":null},{"paper_doi":"10.1002/ajh.70405","tag_type":"modality","value":"Allogeneic Stem Cell Transplantation","value_numeric":null},{"paper_doi":"10.1002/ajh.70405","tag_type":"modality","value":"Erythroid Maturation Agent","value_numeric":null},{"paper_doi":"10.1002/ajh.70405","tag_type":"modality","value":"Hypomethylating Agent","value_numeric":null},{"paper_doi":"10.1002/ajh.70405","tag_type":"modality","value":"Immunomodulatory Agent","value_numeric":null},{"paper_doi":"10.1002/ajh.70405","tag_type":"modality","value":"Intensive Chemotherapy","value_numeric":null},{"paper_doi":"10.1002/ajh.70405","tag_type":"modality","value":"Telomerase Inhibitor","value_numeric":null},{"paper_doi":"10.1002/ajh.70405","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1002/ajh.70405","tag_type":"study_design","value":"Narrative Review / Clinical Update","value_numeric":null},{"paper_doi":"10.1002/ajh.70405","tag_type":"warning","value":"Brand name assignments (Reblozyl, Inqovi, Rytelo) are based on standard drug knowledge and not explicitly stated in the source text.","value_numeric":null},{"paper_doi":"10.1002/ajh.70405","tag_type":"warning","value":"The abstract does not specify exact patient population sizes or trial-level effect estimates; numeric tags could not be assigned for sample size.","value_numeric":null},{"paper_doi":"10.1002/ajh.70405","tag_type":"warning","value":"This is a review/update article, not a primary study — no new trial data or patient-level outcomes are reported in the abstract. Level of evidence reflects the review design.","value_numeric":null}],"summaries":{"what_studied":"This is a 2026 update review covering diagnosis, risk-stratification, and management of myelodysplastic syndromes (MDS/myelodysplastic neoplasms), including the 2022 WHO classification, prognostic scoring systems (IPSS-R, IPSS-M), and available therapies across risk groups.","key_result":"AlloSCT remains the only curative option. Approved US therapies now include luspatercept (2020), oral decitabine/cedazuridine (2020), and imetelstat (2024) for transfusion-dependent lower-risk MDS. No combination regimen has proven superior to single-agent azacitidine, and no approved options exist for HMA-refractory disease.","limitations":"As a narrative review/update, it does not present new primary trial data or meta-analytic pooling. Evidence quality for individual recommendations varies and is not formally graded within the abstract.","practice_takeaway":"Risk-stratify all MDS patients using IPSS-R and IPSS-M to guide therapy selection, including transplant eligibility. For transfusion-dependent lower-risk MDS, imetelstat (approved 2024) is now an option alongside luspatercept; no approved therapy exists for HMA-refractory disease, so clinical trial enrollment should be prioritized."}},{"doi":"10.1182/blood.2025032290","pmid":"42227898","title":"Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis","journal_title":"Blood Journal","journal_issn":"0006-4971","published_at":"2026-06-02T00:00:00.000Z","url":"https://doi.org/10.1182/blood.2025032290","source_score":40,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-03T13:44:41.010Z","updated_at":"2026-06-03T13:44:41.010Z","tags":[{"paper_doi":"10.1182/blood.2025032290","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1182/blood.2025032290","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1182/blood.2025032290","tag_type":"condition","value":"Sickle Cell Disease","value_numeric":null},{"paper_doi":"10.1182/blood.2025032290","tag_type":"generic","value":"hydroxyurea","value_numeric":null},{"paper_doi":"10.1182/blood.2025032290","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1182/blood.2025032290","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.1182/blood.2025032290","tag_type":"modality","value":"Allogeneic Stem Cell Transplantation","value_numeric":null},{"paper_doi":"10.1182/blood.2025032290","tag_type":"modality","value":"Gene Therapy","value_numeric":null},{"paper_doi":"10.1182/blood.2025032290","tag_type":"modality","value":"Hydroxyurea","value_numeric":null},{"paper_doi":"10.1182/blood.2025032290","tag_type":"sample_size","value":"n=10000","value_numeric":10000},{"paper_doi":"10.1182/blood.2025032290","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1182/blood.2025032290","tag_type":"study_design","value":"Cost-Effectiveness Analysis","value_numeric":null},{"paper_doi":"10.1182/blood.2025032290","tag_type":"warning","value":"Gene therapy brand names (e.g., Lyfgenia, Casgevy) are not specified in the abstract; no brand or specific generic GT tags were added.","value_numeric":null},{"paper_doi":"10.1182/blood.2025032290","tag_type":"warning","value":"Level of evidence assigned as 4 (modeling study); the underlying clinical data come from two prospective studies whose quality and follow-up duration are not fully described in the abstract.","value_numeric":null},{"paper_doi":"10.1182/blood.2025032290","tag_type":"warning","value":"Sample size of n=10,000 refers to Monte Carlo simulation iterations, not a clinical patient cohort — interpret accordingly.","value_numeric":null}],"summaries":{"what_studied":"This cost-effectiveness analysis compared non-myeloablative haploidentical allogeneic stem cell transplantation (NMAC-HID allo-HSCT), gene therapy (GT), and standard of care (SOC: hydroxyurea, pain management, blood transfusion) in adults and children with sickle cell disease (SCD), using a Markov model with 10,000 Monte Carlo simulations.","key_result":"SOC, NMAC-HID allo-HSCT, and GT yielded 14.3, 20.1, and 22.1 QALYs at costs of $1.22M, $1.15M, and $2.75M respectively; NMAC-HID allo-HSCT was cost-effective versus GT in 100% of 10,000 simulations. The maximum cost-effective GT price threshold was $1.4M (US) and $4,200–$22,000 (India, Nigeria, Tanzania).","limitations":"The analysis relies on two prospective studies for NMAC-HID allo-HSCT efficacy data, which may have limited follow-up; GT pricing is still under negotiation, making threshold estimates sensitive to future price changes; generalizability across health systems with very different willingness-to-pay values may be limited.","practice_takeaway":"NMAC-HID allo-HSCT offers a cost-effective alternative to gene therapy for SCD, generating similar QALYs at roughly half the cost — clinicians and payers should weigh it as the preferred curative-intent strategy until GT prices fall substantially. In low- and middle-income countries, current GT pricing far exceeds cost-effective thresholds, making haploidentical transplant the more accessible option."}},{"doi":"10.1097/moh.0000000000000906","pmid":"41496439","title":"Navigating prognostic stratification and approach to TP53-mutated myeloid neoplasms","journal_title":"Current Opinion in Hematology","journal_issn":"1065-6251","published_at":"2026-01-07T00:00:00.000Z","url":"https://doi.org/10.1097/moh.0000000000000906","source_score":11,"is_retracted":false,"is_open_access":null,"raw_metadata":{"ooir":{"day":"2026-01-08","doi":"10.1097/moh.0000000000000906","days":"7","issn":"1065-6251","rank":"10","field":"Clinical Medicine","score":"11","category":"Hematology","categories":["Hematology"],"_categories":["Hematology"]},"pubmed":{"doi":"10.1097/MOH.0000000000000906","title":"Navigating prognostic stratification and approach to TP53-mutated myeloid neoplasms.","journal":"Current opinion in hematology","methods":"","results":"","abstract":"$30","keywords":["acute myeloid leukemia","allogeneic hematopoietic stem cell transplantation","myelodysplastic syndrome","myeloproliferative neoplasm"],"pubmed_id":"41496439","conclusions":"","publication_date":"2026-01-07T00:00:00"},"crossref":{"DOI":"10.1097/moh.0000000000000906","URL":"https://doi.org/10.1097/moh.0000000000000906","ISSN":["1065-6251","1531-7048"],"link":[{"URL":"https://journals.lww.com/10.1097/MOH.0000000000000906","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Navigating prognostic stratification and approach to TP53-mutated myeloid neoplasms"],"author":[{"given":"Talha","family":"Badar","sequence":"first","affiliation":[{"name":"Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, Florida"}]},{"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA"}]},{"given":"Naseema","family":"Gangat","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA"}]}],"issued":{"date-parts":[[2025,12,30]]},"member":"276","prefix":"10.1097","source":"Crossref","volume":null,"created":{"date-time":"2026-01-07T07:01:00Z","timestamp":1767769260000,"date-parts":[[2026,1,7]]},"indexed":{"date-time":"2026-01-07T07:03:27Z","timestamp":1767769407854,"date-parts":[[2026,1,7]]},"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://journals.lww.com/10.1097/MOH.0000000000000906"}},"subtitle":[],"deposited":{"date-time":"2026-01-07T07:01:07Z","timestamp":1767769267000,"date-parts":[[2026,1,7]]},"issn-type":[{"type":"print","value":"1065-6251"},{"type":"electronic","value":"1531-7048"}],"published":{"date-parts":[[2025,12,30]]},"publisher":"Ovid Technologies (Wolters Kluwer Health)","reference":[{"DOI":"10.1038/s41408-024-01186-5","key":"R1-20260107","year":"2024","issue":null,"author":"Shahzad","volume":"14","first-page":"202","unstructured":null,"article-title":"What have we learned about TP53-mutated acute myeloid leukemia?","journal-title":"Blood Cancer J","doi-asserted-by":"crossref"},{"DOI":"10.1111/bjh.20187","key":"R2-20260107","year":"2025","issue":null,"author":"Badar","volume":"207","first-page":"683","unstructured":null,"article-title":"Heterogeneity in outcomes of TP53-mutated myeloproliferative neoplasms based on disease phenotype and mutational status","journal-title":"Br J Haematol","doi-asserted-by":"crossref"},{"DOI":"10.1002/ajh.27609","key":"R3-20260107","year":"2025","issue":null,"author":"Tefferi","volume":"100","first-page":"552","unstructured":null,"article-title":"TP53 mutations in myeloproliferative neoplasms: context-dependent evaluation of prognostic relevance","journal-title":"Am J Hematol","doi-asserted-by":"crossref"},{"DOI":"10.1038/35042675","key":"R4-20260107","year":"2000","issue":null,"author":"Vogelstein","volume":"408","first-page":"307","unstructured":null,"article-title":"Surfing the p53 network","journal-title":"Nature","doi-asserted-by":"crossref"},{"DOI":"10.1002/ajh.26546","key":"R5-20260107","year":"2022","issue":null,"author":"Badar","volume":"97","first-page":"E232","unstructured":null,"article-title":"Outcomes of TP53-mutated AML with evolving frontline therapies: impact of allogeneic stem cell transplantation on survival","journal-title":"Am J Hematol","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood.2024027408","key":"R6-20260107","year":"2025","issue":null,"author":"Zeidner","volume":"146","first-page":"590","unstructured":null,"article-title":"Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1182/bloodadvances.2024015335","key":"R8-20260107","year":"2025","issue":null,"author":"Baranwal","volume":"9","first-page":"3395","unstructured":null,"article-title":"Factors associated with survival after allogeneic transplantation for myeloid neoplasms harboring TP53 mutations","journal-title":"Blood Adv","doi-asserted-by":"crossref"},{"DOI":"10.18632/oncotarget.28652","key":"R9-20260107","year":"2024","issue":null,"author":"Badar","volume":"15","first-page":"674","unstructured":null,"article-title":"Transplant or no transplant for TP53 mutated AML","journal-title":"Oncotarget","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood.2022015850","key":"R10-20260107","year":"2022","issue":null,"author":"Arber","volume":"140","first-page":"1200","unstructured":null,"article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1038/s41375-022-01613-1","key":"R11-20260107","year":"2022","issue":null,"author":"Khoury","volume":"36","first-page":"1703","unstructured":null,"article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms","journal-title":"Leukemia","doi-asserted-by":"crossref"},{"DOI":"10.1126/science.aax3649","key":"R12-20260107","year":"2019","issue":null,"author":"Boettcher","volume":"365","first-page":"599","unstructured":null,"article-title":"A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies","journal-title":"Science","doi-asserted-by":"crossref"},{"DOI":null,"key":"R13-20260107","year":"2024","issue":null,"author":"Badar","volume":"109","first-page":"3533","unstructured":null,"article-title":"Prognostic impact of ’multihit’ versus 'single-hit’ TP53 alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases","journal-title":"Haematologica","doi-asserted-by":null},{"DOI":"10.1182/blood.2021014472","key":"R14-20260107","year":"2022","issue":null,"author":"Grob","volume":"139","first-page":"2347","unstructured":null,"article-title":"Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood.2023022222","key":"R15-20260107","year":"2023","issue":null,"author":"Weeks","volume":"142","first-page":"2235","unstructured":null,"article-title":"Causes and consequences of clonal hematopoiesis","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":null,"key":"R16-20260107","year":"2020","issue":null,"author":"Challen","volume":"136","first-page":"1590","unstructured":null,"article-title":"Clonal hematopoiesis: mechanisms driving dominance of stem cell clones","journal-title":"Blood","doi-asserted-by":null},{"DOI":"10.1182/blood-2024-202688","key":"R17-20260107","year":"2024","issue":"(Suppl 1)","author":"Badar","volume":"144","first-page":"3218","unstructured":null,"article-title":"PPM1D somatic mutations in myeloid neoplasms: clinical profile, clonal characteristics and impact of concurrent somatic TP53 mutations","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood.2022018236","key":"R18-20260107","year":"2023","issue":null,"author":"Hiwase","volume":"141","first-page":"1087","unstructured":null,"article-title":"TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1200/JCO.2001.19.5.1405","key":"R19-20260107","year":"2001","issue":null,"author":"Christiansen","volume":"19","first-page":"1405","unstructured":null,"article-title":"Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis","journal-title":"J Clin Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1056/EVIDoa2200008","key":"R20-20260107","year":"2022","issue":null,"author":"Bernard","volume":"1","first-page":"EVIDoa2200008","unstructured":null,"article-title":"Molecular international prognostic scoring system for myelodysplastic syndromes","journal-title":"NEJM Evid","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood.2022016867","key":"R21-20260107","year":"2022","issue":null,"author":"Döhner","volume":"140","first-page":"1345","unstructured":null,"article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood.2024025409","key":"R22-20260107","year":"2024","issue":null,"author":"Döhner","volume":"144","first-page":"2169","unstructured":null,"article-title":"Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood-2012-03-420489","key":"R23-20260107","year":"2012","issue":null,"author":"Greenberg","volume":"120","first-page":"2454","unstructured":null,"article-title":"Revised International Prognostic Scoring System for myelodysplastic syndromes","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1056/EVIDoa2200008","key":"R24-20260107","year":"2022","issue":null,"author":"Bernard","volume":"1","first-page":"EVIDoa2200008","unstructured":null,"article-title":"Molecular International Prognostic Scoring System for Myelodysplastic Syndromes","journal-title":"NEJM Evid","doi-asserted-by":"crossref"},{"DOI":"10.1038/s41375-023-01962-5","key":"R25-20260107","year":"2023","issue":null,"author":"Alaggio","volume":"37","first-page":"1944","unstructured":null,"article-title":"Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms”. Leukemia. 2022 Jul;36(7):1720–1748","journal-title":"Leukemia","doi-asserted-by":"crossref"},{"DOI":"10.1200/JCO.2010.32.2446","key":"R26-20260107","year":"2011","issue":null,"author":"Gangat","volume":"29","first-page":"392","unstructured":null,"article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","journal-title":"J Clin Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1200/JCO.2017.76.4886","key":"R27-20260107","year":"2018","issue":null,"author":"Guglielmelli","volume":"36","first-page":"310","unstructured":null,"article-title":"MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis","journal-title":"J Clin Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1200/JCO.2018.78.9867","key":"R28-20260107","year":"2018","issue":null,"author":"Tefferi","volume":"36","first-page":"1769","unstructured":null,"article-title":"MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis","journal-title":"J Clin Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.bneo.2024.100004","key":"R29-20260107","year":"2024","issue":null,"author":"Jambhekar","volume":"1","first-page":"100004","unstructured":null,"article-title":"Comparison of TP53 mutations in myelodysplasia and acute leukemia suggests divergent roles in initiation and progression","journal-title":"Blood Neoplasia","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood.2020006158","key":"R30-20260107","year":"2020","issue":null,"author":"Sallman","volume":"136","first-page":"2812","unstructured":null,"article-title":"TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood.2024024245","key":"R31-20260107","year":"2025","issue":null,"author":"Sallman","volume":"145","first-page":"2828","unstructured":null,"article-title":"TP53-mutated acute myeloid leukemia: how can we improve outcomes?","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1038/leu.2008.173","key":"R32-20260107","year":"2009","issue":null,"author":"Bowen","volume":"23","first-page":"203","unstructured":null,"article-title":"TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis","journal-title":"Leukemia","doi-asserted-by":"crossref"},{"DOI":"10.1136/jcp-2024-209954","key":"R33-20260107","year":"2025","issue":null,"author":"Pandiri","volume":"78","first-page":"629","unstructured":null,"article-title":"Karyotypic clonal fraction predicts adverse outcome in TP53-mutated myeloid neoplasms: an International TP53 investigators Network (iTiN) study","journal-title":"J Clin Pathol","doi-asserted-by":"crossref"},{"DOI":"10.1200/JCO.2017.77.6112","key":"R34-20260107","year":"2018","issue":null,"author":"Lancet","volume":"36","first-page":"2684","unstructured":null,"article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","journal-title":"J Clin Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood-2018-99-117772","key":"R35-20260107","year":"2018","issue":"(Suppl 1)","author":"Goldberg","volume":"132","first-page":"1433","unstructured":null,"article-title":"TP53 mutations predict poorer responses to CPX-351 in acute myeloid leukemia","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1038/s41375-025-02531-8","key":"R36-20260107","year":"2025","issue":null,"author":"DiNardo","volume":"39","first-page":"854","unstructured":null,"article-title":"Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia","journal-title":"Leukemia","doi-asserted-by":"crossref"},{"DOI":"10.2147/CMAR.S271442","key":"R37-20260107","year":"2022","issue":null,"author":"Moreno Vanegas","volume":"14","first-page":"3527","unstructured":null,"article-title":"Clinical utility of azacitidine in the management of acute myeloid leukemia: update on patient selection and reported outcomes","journal-title":"Cancer Manag Res","doi-asserted-by":"crossref"},{"DOI":"10.1200/JCO.2009.23.8329","key":"R38-20260107","year":"2010","issue":null,"author":"Fenaux","volume":"28","first-page":"562","unstructured":null,"article-title":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia","journal-title":"J Clin Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa2012971","key":"R39-20260107","year":"2020","issue":null,"author":"DiNardo","volume":"383","first-page":"617","unstructured":null,"article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1038/s41408-024-01000-2","key":"R40-20260107","year":"2024","issue":null,"author":"Badar","volume":"14","first-page":"32","unstructured":null,"article-title":"Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)","journal-title":"Blood Cancer J","doi-asserted-by":"crossref"},{"DOI":"10.1002/ajh.27138","key":"R41-20260107","year":"2024","issue":null,"author":"Gangat","volume":"99","first-page":"193","unstructured":null,"article-title":"Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: genotype signatures for response and survival among 301 consecutive patients","journal-title":"Am J Hematol","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood.2024025464","key":"R42-20260107","year":"2025","issue":null,"author":"Garcia","volume":"145","first-page":"1126","unstructured":null,"article-title":"Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood-2024-203825","key":"R44-20260107","year":"2024","issue":null,"author":"Badar","volume":"144","first-page":"1823","unstructured":null,"article-title":"Venetoclax in combination with hypomethylating agent (HMA) compared to HMA alone improves response but not survival in TP53-mutated high-risk myelodysplastic syndrome: real-world mayo clinic series","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1200/JCO.20.02342","key":"R45-20260107","year":"2021","issue":null,"author":"Cluzeau","volume":"39","first-page":"1575","unstructured":null,"article-title":"Eprenetapopt plus azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II Study by the Groupe Francophone des Myélodysplasies (GFM)","journal-title":"J Clin Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood.2024027506","key":"R46-20260107","year":"2025","issue":null,"author":"Daver","volume":"146","first-page":"601","unstructured":null,"article-title":"The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1200/JCO.22.02604","key":"R48-20260107","year":"2023","issue":null,"author":"Daver","volume":"41","first-page":"4893","unstructured":null,"article-title":"Tolerability and efficacy of the anticluster of differentiation 47 antibody magrolimab combined with azacitidine in patients with previously untreated AML: phase Ib results","journal-title":"J Clin Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1182/bloodadvances.2024014553","key":"R49-20260107","year":"2025","issue":null,"author":"Badar","volume":"9","first-page":"239","unstructured":null,"article-title":"T-cell immune cluster analysis using CyTOF identifies unique subgroups of patients with acute myeloid leukemia","journal-title":"Blood Adv","doi-asserted-by":"crossref"},{"DOI":"10.1038/leu.2017.230","key":"R50-20260107","year":"2018","issue":null,"author":"Kubesova","volume":"32","first-page":"450","unstructured":null,"article-title":"Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status","journal-title":"Leukemia","doi-asserted-by":"crossref"},{"DOI":"10.1002/ajh.27670","key":"R51-20260107","year":"2025","issue":null,"author":"Fathima","volume":"100","first-page":"1010","unstructured":null,"article-title":"Multihit TP53 mutations in myeloproliferative neoplasms and acute myeloid leukemia: comparative analysis of survival and risk factors in 142 informative cases","journal-title":"Am J Hematol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.leukres.2015.06.001","key":"R52-20260107","year":"2015","issue":null,"author":"Badar","volume":"39","first-page":"950","unstructured":null,"article-title":"Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase","journal-title":"Leuk Res","doi-asserted-by":"crossref"},{"DOI":"10.1002/ajh.26186","key":"R53-20260107","year":"2021","issue":null,"author":"Gangat","volume":"96","first-page":"781","unstructured":null,"article-title":"Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: a multicenter series of 32 consecutive cases","journal-title":"Am J Hematol","doi-asserted-by":"crossref"},{"DOI":"10.1038/s41375-018-0019-y","key":"R54-20260107","year":"2018","issue":null,"author":"Tefferi","volume":"32","first-page":"1200","unstructured":null,"article-title":"Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts","journal-title":"Leukemia","doi-asserted-by":"crossref"},{"DOI":"10.1002/ajh.26833","key":"R55-20260107","year":"2023","issue":null,"author":"Ortí","volume":"98","first-page":"628","unstructured":null,"article-title":"Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation","journal-title":"Am J Hematol","doi-asserted-by":"crossref"},{"DOI":"10.1038/s41408-023-00878-8","key":"R56-20260107","year":"2023","issue":null,"author":"Tefferi","volume":"13","first-page":"108","unstructured":null,"article-title":"Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm","journal-title":"Blood Cancer J","doi-asserted-by":"crossref"},{"DOI":"10.1111/bjh.13912","key":"R57-20260107","year":"2016","issue":null,"author":"Middeke","volume":"172","first-page":"914","unstructured":null,"article-title":"TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation","journal-title":"Br J Haematol","doi-asserted-by":"crossref"},{"DOI":"10.1111/bjh.12253","key":"R58-20260107","year":"2013","issue":null,"author":"Mohr","volume":"161","first-page":"237","unstructured":null,"article-title":"Impact of allogeneic haematopoietic stem cell transplantation in patients with abnl(17p) acute myeloid leukaemia","journal-title":"Br J Haematol","doi-asserted-by":"crossref"},{"DOI":"10.1038/s41375-023-01847-7","key":"R59-20260107","year":"2023","issue":null,"author":"Badar","volume":"37","first-page":"799","unstructured":null,"article-title":"Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)","journal-title":"Leukemia","doi-asserted-by":"crossref"},{"DOI":"10.1182/bloodadvances.2024014499","key":"R60-20260107","year":"2025","issue":null,"author":"Lontos","volume":"9","first-page":"2845","unstructured":null,"article-title":"TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS/AML for transplantation","journal-title":"Blood Adv","doi-asserted-by":"crossref"}],"short-title":[],"update-policy":"https://doi.org/10.1097/lww.0000000000001000","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Current Opinion in Hematology"],"reference-count":57,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,12,30]]},"references-count":57,"short-container-title":[],"is-referenced-by-count":0},"unpaywall":null},"created_at":"2026-01-11T11:19:33.869Z","updated_at":"2026-01-11T11:19:33.869Z","tags":[{"paper_doi":"10.1097/moh.0000000000000906","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1097/moh.0000000000000906","tag_type":"condition","value":"Myeloid Neoplasms","value_numeric":null},{"paper_doi":"10.1097/moh.0000000000000906","tag_type":"level_of_evidence","value":"7","value_numeric":null},{"paper_doi":"10.1097/moh.0000000000000906","tag_type":"modality","value":"Allogeneic Stem Cell Transplantation","value_numeric":null},{"paper_doi":"10.1097/moh.0000000000000906","tag_type":"modality","value":"Anti-CD47 Antibody","value_numeric":null},{"paper_doi":"10.1097/moh.0000000000000906","tag_type":"modality","value":"p53 Reactivator","value_numeric":null},{"paper_doi":"10.1097/moh.0000000000000906","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1097/moh.0000000000000906","tag_type":"warning","value":"Population details (age/sex) and disease subtype breakdown are not specified in the abstract.","value_numeric":null},{"paper_doi":"10.1097/moh.0000000000000906","tag_type":"warning","value":"Review article; not a primary study and lacks numerical outcomes in the abstract.","value_numeric":null}],"summaries":{"what_studied":"Narrative review of TP53‑mutated myeloid neoplasms covering prognostic stratification by disease state, TP53 allelic burden, and co‑occurring cytogenetic/molecular changes, and current and emerging treatments (allogeneic transplant, p53 reactivators, anti‑CD47 antibodies).","key_result":"Allogeneic stem cell transplantation is the only intervention reported to offer long‑term survival in selected patients; novel approaches (p53 reactivators, anti‑CD47 antibodies with standard care) have not yet changed the natural history.","limitations":"Narrative review without quantitative outcomes in the abstract; no sample sizes or effect estimates are provided; prognostic models are noted to incompletely capture heterogeneity within TP53‑mutated disease.","practice_takeaway":"Refer eligible patients for allogeneic transplantation when feasible. Use disease state, TP53 allelic burden, and co‑mutations to refine prognosis; recognize that investigational agents (p53 reactivators, anti‑CD47 antibodies) remain non‑transformative to date."}}],"initialOffset":3,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"modality","value":"Allogeneic Stem Cell Transplantation"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Modalities","href":"/hub/tag/modality"},{"name":"Allogeneic Stem Cell Transplantation"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"modality","hub_tag_value":"Allogeneic Stem Cell Transplantation"}}}]]

Papers